Alzheimer's Disease Risk Genes and Mechanisms of Disease Pathogenesis

Overview

Journal Biol Psychiatry

Publisher Elsevier

Specialty Psychiatry

Date 2014 Jun 22

PMID 24951455

Citations 623

Authors

Celeste M Karch

Alison M Goate

Affiliations

Soon will be listed here.

Abstract

We review the genetic risk factors for late-onset Alzheimer's disease (AD) and their role in AD pathogenesis. More recent advances in understanding of the human genome-technologic advances in methods to analyze millions of polymorphisms in thousands of subjects-have revealed new genes associated with AD risk, including ABCA7, BIN1, CASS4, CD33, CD2AP, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB5-DBR1, INPP5D, MS4A, MEF2C, NME8, PICALM, PTK2B, SLC24H4-RIN3, SORL1, and ZCWPW1. Emerging technologies to analyze the entire genome in large data sets have also revealed coding variants that increase AD risk: PLD3 and TREM2. We review the relationship between these AD risk genes and the cellular and neuropathologic features of AD. Understanding the mechanisms underlying the association of these genes with risk for disease will provide the most meaningful targets for therapeutic development to date.

Citing Articles

Identifying shared diagnostic genes and mechanisms in vascular dementia and Alzheimer's disease via bioinformatics and machine learning.

Zheng W, Lin D, Shi S, Ren J, Wu J, Wang M J Alzheimers Dis Rep. 2025; 8(1):1558-1572.

PMID: 40034343 PMC: 11863729. DOI: 10.1177/25424823241289804.

Mitochondrial Dysfunction in Neurodegenerative Diseases: Mechanisms and Corresponding Therapeutic Strategies.

Meng K, Jia H, Hou X, Zhu Z, Lu Y, Feng Y Biomedicines. 2025; 13(2).

PMID: 40002740 PMC: 11852430. DOI: 10.3390/biomedicines13020327.

Nanoscale drug formulations for the treatment of Alzheimer's disease progression.

Liu L, He H, Du B, He Y RSC Adv. 2025; 15(6):4031-4078.

PMID: 39926227 PMC: 11803502. DOI: 10.1039/d4ra08128e.

The global research of magnetic resonance imaging in Alzheimer's disease: a bibliometric analysis from 2004 to 2023.

Sun X, Zhu J, Li R, Peng Y, Gong L Front Neurol. 2025; 15:1510522.

PMID: 39882364 PMC: 11774745. DOI: 10.3389/fneur.2024.1510522.

The potential link between the development of Alzheimer's disease and osteoporosis.

Nasme F, Behera J, Tyagi P, Debnath N, Falcone J, Tyagi N Biogerontology. 2025; 26(1):43.

PMID: 39832071 DOI: 10.1007/s10522-024-10181-z.

References

Crocker P, Hartnell A, Munday J, Nath D . The potential role of sialoadhesin as a macrophage recognition molecule in health and disease. Glycoconj J. 1997; 14(5):601-9. DOI: 10.1023/a:1018588526788. View

Wildsmith K, Holley M, Savage J, Skerrett R, Landreth G . Evidence for impaired amyloid β clearance in Alzheimer's disease. Alzheimers Res Ther. 2013; 5(4):33. PMC: 3978761. DOI: 10.1186/alzrt187. View

Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S . Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb. 2010; 18(4):274-81. DOI: 10.5551/jat.6726. View

Cai D, Zhong M, Wang R, Netzer W, Shields D, Zheng H . Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A. 2006; 103(6):1936-40. PMC: 1413666. DOI: 10.1073/pnas.0510710103. View

Matsubara E, Frangione B, Ghiso J . Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem. 1995; 270(13):7563-7. DOI: 10.1074/jbc.270.13.7563. View

Schurmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller S, Pentzek M . Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis. 2011; 25(3):421-4. DOI: 10.3233/JAD-2011-110251. View

Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard A, Rollin-Sillaire A . TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis. 2013; 35(1):45-9. DOI: 10.3233/JAD-122311. View

Griciuc A, Serrano-Pozo A, Parrado A, Lesinski A, Asselin C, Mullin K . Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013; 78(4):631-43. PMC: 3706457. DOI: 10.1016/j.neuron.2013.04.014. View

Naj A, Jun G, Beecham G, Wang L, Vardarajan B, Buros J . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5):436-41. PMC: 3090745. DOI: 10.1038/ng.801. View

10.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

11.

Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 45(12):1452-8. PMC: 3896259. DOI: 10.1038/ng.2802. View

12.

Velazquez P, Cribbs D, Poulos T, Tenner A . Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med. 1997; 3(1):77-9. DOI: 10.1038/nm0197-77. View

13.

Scherzer C, Offe K, Gearing M, Rees H, Fang G, Heilman C . Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004; 61(8):1200-5. DOI: 10.1001/archneur.61.8.1200. View

14.

Zhang B, Koh Y, Beckstead R, Budnik V, Ganetzky B, Bellen H . Synaptic vesicle size and number are regulated by a clathrin adaptor protein required for endocytosis. Neuron. 1999; 21(6):1465-75. DOI: 10.1016/s0896-6273(00)80664-9. View

15.

Kauwe J, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P . Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008; 105(23):8050-4. PMC: 2430357. DOI: 10.1073/pnas.0801227105. View

16.

Xing Y, Yu J, Cui W, Zhong X, Wu Z, Zhang Q . Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J Alzheimers Dis. 2012; 29(3):515-9. DOI: 10.3233/JAD-2011-111844. View

17.

Jin J, Ahn B, Na Y, Kim J, Kim Y, Choi E . Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease. Neurobiol Aging. 2006; 28(7):1015-27. DOI: 10.1016/j.neurobiolaging.2006.05.022. View

18.

Howie D, Nolan K, Daley S, Butterfield E, Adams E, Garcia-Rueda H . MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation. J Immunol. 2009; 183(7):4197-204. DOI: 10.4049/jimmunol.0901070. View

19.

Spoelgen R, von Arnim C, Thomas A, Peltan I, Koker M, Deng A . Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci. 2006; 26(2):418-28. PMC: 6674411. DOI: 10.1523/JNEUROSCI.3882-05.2006. View

20.

Guerreiro R, Bras J, Hardy J . SnapShot: genetics of Alzheimer's disease. Cell. 2013; 155(4):968-968.e1. DOI: 10.1016/j.cell.2013.10.037. View